Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models

Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models

Abstract Background Tyrosine kinase inhibitors (TKIs) are mainstays of cancer treatment. However, their clinical benefits are often constrained by acquired resistance. To overcome such outcomes, we have rationally engineered APG-2449 as a novel multikinase inhibitor that is highly potent against onc...

Full description

Bibliographic Details
Main Authors: Douglas D. Fang, Ran Tao, Guangfeng Wang, Yuanbao Li, Kaixiang Zhang, Chunhua Xu, Guoqin Zhai, Qixin Wang, Jingwen Wang, Chunyang Tang, Ping Min, Dengkun Xiong, Jianyong Chen, Shaomeng Wang, Dajun Yang, Yifan Zhai
Format: Article
Language:English
Published: BMC 2022-07-01
Series:BMC Cancer
Subjects:
Anaplastic lymphoma kinase (ALK)
Focal adhesion kinase (FAK)
ROS proto-oncogene 1 receptor tyrosine kinase (ROS1)
Solid tumors
Targeted therapies
Online Access:https://doi.org/10.1186/s12885-022-09799-4

Internet

https://doi.org/10.1186/s12885-022-09799-4

Similar Items